Serum prohepcidin concentrations in rheumatoid arthritis and its relation to disease activity
Egyptian Rheumatology and Rehabilitation volume 41, pages 130–134 (2014)
The aim of this study was to assess the possible relations between serum level of prohepcidin in patients with rheumatoid arthritis (RA) and their rheumatoid anemia profiles and disease activity.
Patients and methods
A total of 80 patients with RA (34 male and 46 female) were enrolled. Their mean age was 43.3 ± 11.5 years, and the mean duration of the disease was 7.7 ± 7.0 years. RA disease activities were measured using Disease Activity Score 28 (DAS28). Anemia profiles were measured. Serum concentration of prohepcidin, the prohormone of hepcidin, was measured using enzyme-linked immunosorbent assay.
The patients’ mean concentration of serum prohepcidin was 211.4 ± 5.88 ng/ml, which was significantly higher than in the control group (167 ± 5.2 ng/ml). Serum level of interleukin-6 and tumor necrosis fact or-α were significantly higher in RA patients than in the healthy control group (21.11 ± 5.88 vs. 3.36 ± 1.3 pg/ml and 17.8 ± 3.7 vs. 3.7 ± 1.1 pg/ml, respectively). The prohepcidin concentration was correlated with rheumatoid factor, C-reactive protein, erythrocyte sedimentation rate, and DAS28. There was a significant correlation between prohepcidin with tumor necrosis fact or-α and interleukin-6. The prohepcidin concentration was significantly higher in the patients with active RA (DAS28 > 5.1) than those with inactive-to-moderate RA (DAS28≤5.1). Serum prohepcidin concentration in patients negatively correlated with serum iron (r = –0.23, P = 0.04). However, the prohepcidin concentration did not correlate with other anemia profiles. There was no difference of prohepcidin concentration between the patients with anemia of chronic disease and those without.
Serum concentration of prohepcidin reflects the disease activity, regardless of the anemia states in RA patients, and thus prohepcidin could be used as another useful marker for RA disease activity.
Szodoray P, Szabó Z, Kapitány A, et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010; 9:140–143.
Wilson A, Yu HT, Goodnough LT, et al. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004; 116:50S–57S.
Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 2002; 31:251–259.
Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008; 35:380–386.
Jayaranee S, Sthaneshwar P, Sokkalingam S. Serum prohepcidin concentrations in rheumatoid arthritis. Pathology 2009; 41:178–182.
Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271–1276.
Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131:788–796.
Lee SY, Song EY, Yun YM, et al. Serum prohepcidin levels in Helicobacter pylori infected patients with iron deficiency anemia. Korean J Intern Med 2010; 25:195–200.
SH Lee, SH Jeong, YS Park, et al. Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease. Korean J Hepatol 2010; 16:288–294.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–324.
Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44–48.
Memoli B, Salerno S, Procino A, et al. A translational approach to micro-inflammation in end-stage renal disease: molecular effects of low levels of interleukin-6. Clin Sci (Lond) 2010; 119:163–174.
Cronstein BN. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65:S11–S15.
Kim HR, Kim KW, Yoon SY, et al. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis, Korean Med Sci 2010; 25:348–352.
Koca SS, Isik A, Ustundag B, et al. Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus. Inflammation. 2008; 31:146–153.
Nicolas G, Chauvet C, Viatte L. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation. J Clin Invest 2002; 110:1037–1044.
Kemna E, Pickkers P, Nemeth E, et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005; 106:1864–1866.
Hadley KB, Johnson LK, Hunt JR. Iron absorption by healthy women is not associated with either serum or urinary prohepcidin. Am J Clin Nutr 2006; 84:150–155.
Bridges, SL, Davidson A, Koppman WJ. In: LW Morelandeditors. Rheumatoid factor. Arthritis and allied conditions: a textbook of rheumatology 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. 1227–1247.
Roe MA, Spinks C, Heath AL, et al. Serum pro-hepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007; 97:544–549.
Taes YE, Wuyts B, Boelaert JR, et al. Pro-hepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004; 42:387–389.
About this article
Cite this article
Emerah, A., Abbas, S.F. & Pasha, H.F. Serum prohepcidin concentrations in rheumatoid arthritis and its relation to disease activity. Egypt Rheumatol Rehabil 41, 130–134 (2014). https://doi.org/10.4103/1110-161X.140530
- anemia of chronic disease
- rheumatoid arthritis